A Phase 2b/3 Prospective, Randomized, Double-Blind, Sham-Controlled 3-Part Trial of 2-hydroxypropyl-β-cyclodextrin (VTS-270) in Subjects With Neurologic Manifestations of Niemann-Pick Type C1 (NPC1) Disease

Trial Profile

A Phase 2b/3 Prospective, Randomized, Double-Blind, Sham-Controlled 3-Part Trial of 2-hydroxypropyl-β-cyclodextrin (VTS-270) in Subjects With Neurologic Manifestations of Niemann-Pick Type C1 (NPC1) Disease

Active, no longer recruiting
Phase of Trial: Phase II/III

Latest Information Update: 13 Feb 2018

At a glance

  • Drugs Adrabetadex (Primary)
  • Indications Niemann-Pick disease type C
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Vtesse
  • Most Recent Events

    • 13 Feb 2018 According to a Mallinckrodt plc media release, Sucampo Pharmaceuticals is acquired by Mallinckrodt.
    • 26 Dec 2017 According to a Mallinckrodt plc media release, the NDA filing is currently expected in 2018.
    • 18 Dec 2017 This trial has been Discontinued in Spain, according to European Clinical Trials Database
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top